(E/Z)-BCI (NSC 150117) 是一种DUSP6抑制剂，具有抗炎活性。(E/Z)-BCI 通过激活 Nrf2 信号和抑制 NF-κB 通路，减弱 LPS 诱导的巨噬细胞炎症和 ROS 生成。
| 生物活性 | (E/Z)-BCI (NSC 150117) is adual-specificityphosphatase6 (DUSP6)inhibitor with anti-inflammatory activities. (E/Z)-BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting theNF-κBpathway[1]. |
| IC50& Target | |
体外研究
(In Vitro) | (E/Z)-BCI hydrochloride (2-10 μM; 72 hours) significantly decreases cell viability in a time and dose-dependent manner in gastric epithelial cell GES1, GC cell lines, and AGS cell lines[2].
(E/Z)-BCI hydrochloride (0.5-4 μM; 24 hours) significantly inhibits DUSP6 expression in LPS-activated macrophages[1].
(E/Z)-BCI hydrochloride (0.5-2 μM; 24 hours) treatment significantly inhibits the expression of IL-1β, TNF-α and IL-6 mRNA in LPS-activated macrophages[1].
(E/Z)-BCI hydrochloride decreases ROS production and activates the Nrf2 pathway in LPS-activated macrophages[1].
(E/Z)-BCI hydrochloride inhibits cell proliferation, migration and invasion in a receptor-independent manner and enhances Cisplatin (CDDP) cytotoxicity (enhances CDDP-induced cell death and apoptosis) at pharmacological concentrations in the gastric cancer (GC) cells[2].
Cell Viability Assay[2] | Cell Line: | Gastric epithelial cell GES1, GC cell lines (HGC27, SGC7901, MKN45, BGC823, MGC803, SNU216, NUGC4), AGS cell lines | | Concentration: | 2 μM, 4 μM, 6 μM, 8 μM, 10 μM | | Incubation Time: | 72 hours | | Result: | Cell viability was significantly decreased in a time and dose-dependent manner. |
Western Blot Analysis[1] | Cell Line: | RAW264.7 macrophage cells (by LPS-activated macrophages) | | Concentration: | 0.5 μM, 1 μM, 2 μM, 4 μM | | Incubation Time: | 24 hours | | Result: | DUSP6 protein was significantly downregulated in LPS-activated macrophages. |
RT-PCR[1] | Cell Line: | RAW264.7 macrophage cells (by LPS-activated macrophages) | | Concentration: | 0.5 μM, 1 μM, 2 μM | | Incubation Time: | 24 hours | | Result: | The expression of IL-1β, TNF-α and IL-6 mRNA was significantly inhibited in
LPS-activated macrophages. |
|
体内研究
(In Vivo) | (E/Z)-BCI hydrochloride (35 mg/kg; intraperitoneal injection; every 7 days; for four weeks; female BALB/c nude mice) treatment enhances cisplatin efficacy in PDX models[2].
| Animal Model: | Patient-derived xenograft (PDX) models (4-5-week-old female BALB/c nude mice)[2] | | Dosage: | 35 mg/kg | | Administration: | Intraperitoneal injection; every 7 days; for four weeks | | Result: | Tumor weights in the PDX models treated plus CDDP were significantly suppressed compared with tumors from PDX model mice treated with either agent alone. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com